Female Humans Male Prospective Studies Sex Factors Urinary Bladder Neoplasms/*etiology Urinary Tract Infections/*complications Bladder cancer Cystitis Urinary bladder neoplasms Urinary tract infections Urothelial carcinoma

Cisplatin/*therapeutic use Female Humans Male Neoadjuvant Therapy/*methods Urinary Bladder/drug effects/pathology Urinary Bladder Neoplasms/*drug therapy/pathology

Administration Intravesical Aged Aged 80 and over BCG Vaccine/*therapeutic use Biopsy Needle Disease-Free Survival Female Humans Immunohistochemistry Immunotherapy/*methods In Situ Hybridization Fluorescence Male Middle Aged Neoplasm Recurrence Local/mortality/*pathology Predictive Value of Tests Prognosis Risk Assessment Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/mortality/pathology/*therapy Bcg Bladder cancer Immunotherapy Personalized therapy Response prediction

Adult Aged Aged 80 and over Female Humans *Magnetic Resonance Imaging Male Middle Aged *Neoplasm Staging/methods/standards Urinary Bladder Neoplasms/*diagnostic imaging bladder cancer diagnostic accuracy magnetic resonance imaging staging systematic review

Epirubicin/*therapeutic use Female Humans Immunotherapy/*methods Male Mitomycin/*therapeutic use *Mycobacterium bovis Urinary Bladder Neoplasms/immunology/pathology/*therapy Bacillus Calmette–Guérin Consistency Epirubicin Gemcitabine Heterogeneity Interferon-Alpha Intravesical instillation therapies Mitomycin C Pairwise/network meta-analysis Tumor progression Tumor recurrence

Aged *Coffee Cohort Studies Female Follow-Up Studies Humans Incidence Japan/epidemiology Male Middle Aged Prospective Studies Risk Factors Surveys and Questionnaires Urinary Bladder Neoplasms/diagnosis/*epidemiology/*prevention & control

Aged Diabetes Mellitus Type 2/complications/*drug therapy Disease Progression Disease-Free Survival Female Humans Hypoglycemic Agents/*therapeutic use Male Metformin/*therapeutic use Middle Aged Prognosis Proportional Hazards Models Retrospective Studies Risk Factors Urinary Bladder Neoplasms/etiology/*mortality

Chemoradiotherapy/*methods Combined Modality Therapy Cystectomy/*adverse effects/methods Disease-Free Survival Female Humans Male Middle Aged Neoplasm Metastasis Robotic Surgical Procedures/*adverse effects/methods Treatment Outcome Urinary Bladder Neoplasms/diagnostic imaging/*therapy Bladder cancer Cystectomy Multi-modality treatment Port-site metastasis Rare complications

Estrogen Receptor alpha/metabolism Estrogen Receptor beta/metabolism Female Humans Immunohistochemistry/*methods Male Prognosis Receptors Androgen/metabolism Retrospective Studies Software Urinary Bladder Neoplasms/*metabolism/pathology

Adenocarcinoma/*etiology Carcinoma Squamous Cell/*etiology Carcinoma Transitional Cell/*etiology Case-Control Studies Cohort Studies Female Humans Male Neoplasm Recurrence Local Recurrence Regression Analysis Retrospective Studies Urinary Bladder Neoplasms/*etiology Urinary Tract Infections/*complications Bladder carcinoma Case–control studies Chronic urinary tract infection Meta-analysis

Aged Aged 80 and over Chemoradiotherapy/*mortality/*statistics & numerical data Combined Modality Therapy Cystectomy/*mortality/*statistics & numerical data Disease-Free Survival Female Humans Male Middle Aged Neoplasm Invasiveness Postoperative Complications/mortality/prevention & control Prevalence Radiation Injuries/mortality/prevention & control Risk Factors Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*mortality/*therapy

Cystectomy/*methods Female Humans Organ Sparing Treatments/*methods Postoperative Complications Sexual Dysfunction Physiological/*prevention & control Treatment Outcome Urinary Bladder/*pathology Urinary Bladder Neoplasms/physiopathology/*surgery Urinary Diversion/*methods Urinary Incontinence/*prevention & control #BladderCancer #blcsm radical cystectomy sexual function urinary bladder neoplasms urinary incontinence

Cystectomy/*adverse effects Diurnal Enuresis/etiology Female Humans Nocturnal Enuresis/etiology *Quality of Life Sexual Dysfunction Physiological/*etiology/physiopathology Urinary Bladder Neoplasms/*surgery Urinary Diversion/adverse effects Urinary Incontinence/*etiology Cystectomy Functional outcomes Gender disparities Outcomes assessment Urinary bladder neoplasms

Administration Intravesical BCG Vaccine/therapeutic use Disease Progression Female Humans *Ki-67 Antigen Male *Neoplasm Invasiveness Prognosis Prospective Studies *Urinary Bladder Neoplasms/diagnosis/drug therapy/pathology Ki67 meta-analysis non-muscular-invasive bladder cancer

Anemia/*complications Cystectomy/*methods Female Humans Male Preoperative Period Proportional Hazards Models Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/*surgery Anemia Bladder cancer Hemoglobin Mortality Recurrence

Asian People/genetics Female Humans Male Microtubule-Associated Proteins/*genetics *Polymorphism Single Nucleotide Urinary Bladder Neoplasms/ethnology/*genetics/pathology White People/genetics

Aged Catheterization Chemotherapy Adjuvant Feasibility Studies Female Humans *Laser Therapy Length of Stay Male Middle Aged Operative Time Postoperative Complications/etiology Time Factors Treatment Outcome Urinary Bladder Neoplasms/drug therapy/pathology/*radiotherapy/*surgery Bladder tumor Laser enucleation of bladder tumor Meta-analysis Transurethral resection of bladder tumor (TURBT)

Age Factors Aged Aged 80 and over Clinical Decision-Making *Cystectomy/adverse effects/mortality Disease-Free Survival Female Geriatric Assessment Humans Life Expectancy Male Middle Aged Neoplasm Invasiveness Odds Ratio Patient Selection Quality of Life Radiotherapy/adverse effects/mortality Risk Factors Time Factors Treatment Outcome Urinary Bladder Neoplasms/mortality/pathology/*therapy Complications Elderly Mibc Outcome

Administration Intravesical Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects BCG Vaccine/administration & dosage Bayes Theorem Deoxycytidine/administration & dosage/analogs & derivatives Disease Progression Epirubicin/administration & dosage Female Humans Isoniazid/administration & dosage Male Middle Aged Mitomycin/administration & dosage Neoplasm Invasiveness Neoplasm Recurrence Local Odds Ratio Randomized Controlled Trials as Topic Risk Factors Time Factors Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/mortality/pathology Gemcitabine efficacy and safety intravesical therapy non-muscle invasive bladder cancer tumor progression tumor recurrence

Aged Aged 80 and over *Biomarkers Tumor Cluster Analysis Cohort Studies Female Gene Expression Profiling Humans Immunohistochemistry Male Middle Aged Mutation Neoplasm Invasiveness Neoplasm Staging Neoplasms Basal Cell/*diagnosis/genetics/*metabolism/mortality Prognosis Survival Analysis Tissue Array Analysis Urinary Bladder Neoplasms/*diagnosis/genetics/*metabolism/mortality Biomarker Bladder cancer